Dr. Salman Ahmed

Marine peptides in lymphoma: surgery at molecular level for therapeutic understanding

• Authors Details :  
• Salman Ahmed,  
• Michael Aschner,  
• Khalaf F. Alsharif,  
• Mamdouh Allahyani,  
• Guang Huang,  
• Chunpeng Wan,  
• Haroon Khan

Journal title : Naunyn-Schmiedeberg's Archives of Pharmacology

Publisher : Springer Science and Business Media LLC

Online ISSN : 1432-1912

43 Views Reviews Article

Lymphoma, the most common form of blood cancer, affects primarily the intricate network of tissues and organs known as the lymphatic system. Globally, it ranks among the leading causes of cancer-related deaths. Although conventional therapies have led to significant advancements, they are accompanied by adverse side effects and present challenges in cases of multidrug resistance, refractory patients, and relapses. This highlights a pressing need for innovative treatment approaches. Extensive research on the anti-lymphoma properties of natural compounds has particularly focused on marine organisms as valuable sources for potential medicinal agents. Among these, anticancer peptides have garnered attention due to their multiple beneficial effects against cancer, coupled with reduced toxicity to normal cells. This review focuses on the molecular mechanisms underlying the anti-lymphoma effects of marine peptides, examining the diverse pathways through which these peptides impact physiological processes. Key effects include modulation of cell viability, induction of apoptosis, cell cycle arrest, antimitotic activity, immunotherapeutic properties, disruption of mitochondrial function and induction of oxidative stress, cancer cell membrane destruction, and interference with microtubule stability. The review also highlights the antibody–drug conjugates (ADCs) derived from marine peptides and their synergistic effects with other anti-lymphoma medications. This knowledge should inspire future study and development of these prospective therapeutic modalities and hasten the investigation and creation of novel lymphoma remedies derived from marine sources.

Article DOI & Crossmark Data

DOI : https://doi.org/10.1007/s00210-025-03901-w

Article Subject Details

• Pharmacokinetics
• Pharmacology
• Pharmacology and toxicology
• Pharmacutics
• Pharmacy
• Pharmacy education

Article Keywords Details

• Lymphoma
• Marines drugs
• Peptides

Article File

Full Text PDF

Article References

• (1). Ahmed S, Alam W, Jeandet P, Aschner M, Alsharif KF, Saso L, Khan H (2022) Therapeutic potential of marine peptides in prostate cancer: mechanistic insights. Marine Drugs 20(8):466
• (2). Ahmed S, Alam W, Aschner M, Filosa R, Cheang WS, Jeandet P, Khan H (2023) Marine cyanobacterial peptides in neuroblastoma: Search for better therapeutic options. Cancers 15(9):2515
• (3). Ahmed S, Alam W, Alsharif KF, Aschner M, Alzahrani FM, Saso L, Khan H (2023a) Therapeutic potential of marine peptides in malignant melanoma. Environ Res 227:115771
• (4). Ahmed S, Alam W, Aschner M, Filosa R, Cheang WS, Jeandet P, Saso L, Khan H (2023b) Marine cyanobacterial peptides in neuroblastoma: search for better therapeutic options. Cancers (Basel) 15(9):2515
• (5). Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O’Connor OA (2018) A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 131(4):397–407
• (6). Angirish B, Sanghavi P, Jankharia B (2020) Pulmonary manifestations of lymphoma: A pictorial essay. Lung India 37(3):263–267
• (7). Anson F, Thayumanavan S, Hardy JA (2021) Exogenous Introduction of Initiator and Executioner Caspases Results in Different Apoptotic Outcomes. JACS Au 1(8):1240–1256
• (8). Aspeslagh S, Stein M, Bahleda R, Hollebecque A, Salles G, Gyan E, Fudio S, Extremera S, Alfaro V, Soto-Matos A, Soria J-C (2017) Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anti-Cancer Drugs 28(3):341–349
• (9). Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue M-H, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R (2021) Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol 40(3):242–251
• (10). Bai R, Friedman SJ, Pettit GR, Hamel E (1992) Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia: Interaction with tubulin and effects on cellular microtubules. Biochem Pharmacol 43(12):2637–2645
• (11). Barboza NM, Medina DJ, Budak-Alpdogan T, Aracil M, Jimeno JM, Bertino JR, Banerjee D (2012) Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biol Ther 13(2):114–122
• (12). Barreca M, Spanò V, Montalbano A, Cueto M, Díaz Marrero AR, Deniz I, Erdo?an A, Luki? Bilela L, Moulin C, Taffin-de-Givenchy E (2020a) Marine anticancer agents: An overview with a particular focus on their chemical classes. Marine Drugs 18(12):619
• (13). Barreca M, Stathis A, Barraja P, Bertoni F (2020b) An overview on anti-tubulin agents for the treatment of lymphoma patients. Pharmacol Ther 211:107552
• (14). Bates D, Eastman A (2017) Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol 83(2):255–268
• (15). Beckwith M, Urba WJ, Longo DL (1993) Growth Inhibition of Human Lymphoma Cell Lines by the Marine Products, Dolastatins 10 and 15. JNCI: J Nat Cancer Institute 85(6):483–488
• (16). Bispo JAB, Pinheiro PS, Kobetz EK (2020) Epidemiology and Etiology of Leukemia and Lymphoma. Cold Spring Harb Perspect Med 10(6):a034819
• (17). Bröckelmann PJ, de Jong MRW, Jachimowicz RD (2020) Targeting DNA repair, cell cycle, and Tumor microenvironment in B cell lymphoma. Cells 9(10):2287
• (18). Brucoli F, Natoli A, Marimuthu P, Borrello MT, Stapleton P, Gibbons S, Schätzlein A (2012) Efficient synthesis and biological evaluation of proximicins A, B and C. Bioorg Med Chem 20(6):2019–2024
• (19). Chaudhry GES, Md Akim A, Sung YY, Sifzizul TMT (2022) Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics. Front Pharmacol 13:842376
• (20). Chen IC, Sethy B, Liou JP (2020) Recent Update of HDAC Inhibitors in Lymphoma. Front Cell Dev Biol 8:576391
• (21). Cheng-Sánchez I, Moya-Utrera F, Porras-Alcalá C, López-Romero JM, Sarabia F (2022) Antibody-drug conjugates containing payloads from marine origin. Marine Drugs 20(8):494
• (22). Chiangjong W, Chutipongtanate S, Hongeng S (2020) Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application. Int J Oncol 57(3):678–696
• (23). Chihara D, Oki Y, Fayad L, Wesson E, Ruben C, Horowitz SB, Woolery J, Feng L, Garg N, Ahmed S, Khouri IF, Fanale MA (2014) Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood 124(21):1748–1748
• (24). Chinnadurai RK, Khan N, Meghwanshi GK, Ponne S, Althobiti M, Kumar R (2023) Current research status of anti-cancer peptides: Mechanism of action, production, and clinical applications. Biomed Pharmacother 164:114996
• (25). Cho Y, Park MN, Noh S, Kang SY, Kim B (2020) Review of Natural Compounds for the Management and Prevention of Lymphoma. Processes 8(9):1164
• (26). Chu Y, Zhou X, Wang X (2021) Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol Oncol 14(1):88
• (27). Chu Y, Liu Y, Fang X, Jiang Y, Ding M, Ge X, Yuan D, Lu K, Li P, Li Y, Xu H, Fan J, Zhou X, Wang X (2022) Global Burden, Risk Factors, and Trends of Non-Hodgkin Lymphoma in 2020 and Projections to 2040: A Population-Based Study. Blood 140(Supplement 1):3844–3845
• (28). Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 378(4):331–344
• (29). Cosenza M, Civallero M, Fiorcari S, Pozzi S, Marcheselli L, Liardo EV, Bari A, Sacchi S (2013) Romidepsin and lenalidomide show a synergistic effect In T-Cell lymphoma cell lines. Blood 122(21):5148
• (30). Cosenza M, Civallero M, Fiorcari S, Pozzi S, Marcheselli L, Bari A, Ferri P, Sacchi S (2016) The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines. Cancer Biol Ther 17(10):1094–1106
• (31). Craik DJ, Kan M-W (2021) How can we improve peptide drug discovery? Learning from the past. Expert Opin Drug Discov 16(12):1399–1402
• (32). Cruciani RA, Barker JL, Zasloff M, Chen HC, Colamonici O (1991) Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc Natl Acad Sci 88(9):3792–3796
• (33). Cueto M, Jensen PR, Fenical W (2000) N-Methylsansalvamide, a cytotoxic cyclic depsipeptide from a marine fungus of the genus Fusarium. Phytochemistry 55(3):223–226
• (34). Dehelean CA, Marcovici I, Soica C, Mioc M, Coricovac D, Iurciuc S, Cretu OM, Pinzaru I (2021) Plant-derived anticancer compounds as new perspectives in drug discovery and alternative therapy. Molecules 26(4)
• (35). Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang Y (2021) Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: A cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematol 8(12):e891–e901
• (36). Donato EM, Fernández-Zarzoso M, Hueso JA, de la Rubia J (2018) Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther 11:4583–4590
• (37). Douglas M (2020) Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients. J Adv Pract Oncol 11(5):521–528
• (38). Ebada SS, Müller WE, Lin W, Proksch P (2019) New acyclic cytotoxic jasplakinolide derivative from the marine sponge Jaspis splendens. Marine Drugs 17(2):100
• (39). Falgàs A, Pallarès V, Unzueta U, Núñez Y, Sierra J, Gallardo A, Alba-Castellón L, Mangues MA, Álamo P, Villaverde A, Vázquez E, Mangues R, Casanova I (2021) Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells. Int J Nanomed 16:1869–1888
• (40). Fermé C, Mateos MV, Szyldergemajn S, Corrado CS, Zucca E, Extremera S, Gianni AM, Vandermeeren A, Ribrag V (2010) Aplidin® (Plitidepsin) Activity In Peripheral T-Cell Lymphoma (PTCL): Final Results. Blood 116(21):1767–1767
• (41). Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduction Targeted Ther 7(1):93
• (42). Gao G, Wang Y, Hua H, Li D, Tang C (2021) Marine antitumor peptide dolastatin 10: Biological activity, structural modification and synthetic chemistry. Marine Drugs 19(7):363
• (43). Gerwick WH, Proteau PJ, Nagle DG, Hamel E, Blokhin A, Slate DL (1994) Structure of Curacin A, a Novel Antimitotic, Antiproliferative and Brine Shrimp Toxic Natural Product from the Marine Cyanobacterium Lyngbya majuscula. J Org Chem 59(6):1243–1245
• (44). Ghaly G, Tallima H, Dabbish E, Badr ElDin N, Abd El-Rahman MK, Ibrahim MA, Shoeib T (2023) Anti-cancer peptides: status and future prospects. Molecules 28(3):1148
• (45). Haioun C, Matasar MJ, Sancho J-M, Viardot A, Hernandez J, Perretti T, McMillan A (2020) POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). J Clin Oncol 38(15):TPS8070
• (46). Han B, Gross H, Goeger DE, Mooberry SL, Gerwick WH (2006) Aurilides B and C, Cancer Cell Toxins from a Papua New Guinea Collection of the Marine Cyanobacterium Lyngbya majuscula. J Nat Prod 69(4):572–575
• (47). He F, Bao J, Zhang X-Y, Tu Z-C, Shi Y-M, Qi S-H (2013) Asperterrestide A, a Cytotoxic Cyclic Tetrapeptide from the Marine-Derived Fungus Aspergillus terreus SCSGAF0162. J Nat Prod 76(6):1182–1186
• (48). Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131(11):1183–1194
• (49). Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58(6):1349–1357
• (50). Hontecillas-Prieto L, Flores-Campos R, Silver A, De Álava E, Hajji N, García-Domínguez DJ (2020) Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. Front Genetics 11:578011
• (51). Huang Y-B, Wang X-F, Wang H-Y, Liu Y, Chen Y (2011) Studies on Mechanism of Action of Anticancer Peptides by Modulation of Hydrophobicity Within a Defined Structural Framework. Mol Cancer Ther 10(3):416–426
• (52). Humeniuk R, Menon LG, Mishra PJ, Saydam G, Longo-Sorbello GSA, Elisseyeff Y, Lewis LD, Aracil M, Jimeno J, Bertino JR, Banerjee D (2007) Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity. Leukemia 21(12):2399–2405
• (53). Ibrahim SR, Edrada-Ebel R, Mohamed GA, Youssef DT, Wray V, Proksch P (2008) Callyaerin G, a new cytotoxic cyclic peptide from the marine sponge Callyspongia aerizusa. ARKIVOC 12:164–171
• (54). Ibrahim SRM, Min CC, Teuscher F, Ebel R, Kakoschke C, Lin W, Wray V, Edrada-Ebel R, Proksch P (2010) Callyaerins A-F and H, new cytotoxic cyclic peptides from the Indonesian marine sponge Callyspongia aerizusa. Bioorg Med Chem 18(14):4947–4956
• (55). Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF (2008) Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 14(10):3105–3112
• (56). I?ykowska K, Rassek K, Korsak D, Przybylski GK (2020) Novel targeted therapies of T cell lymphomas. J Hematol Oncol 13(1):176
• (57). Jagadeesh D, Smith MR (2016) Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma. Curr Treatment Options Oncol 17(10):55
• (58). Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O’Connor OA (2015) Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clin Cancer Res 21(9):2096–2106
• (59). Kim K, Park M-H (2024) Role of functionalized peptides in nanomedicine for effective cancer therapy. Biomedicines 12(1):202
• (60). Kim SJ, Kim HS, Seo YR (2019) Understanding of ROS-Inducing Strategy in Anticancer Therapy. Oxid Med Cell Longev 2019:5381692
• (61). Kubra Acikalin C, Merve T, Elif Cansu A, Nazlican Y, Mervenur A, Yusuf T (2022) Drugs and drug candidates for the treatment of lymphoma. IntechOpen
• (62). Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth PA (2000) Phase II Trial of Didemnin B in Previously Treated Non-Hodgkin’s Lymphoma: An Eastern Cooperative Oncology Group (ECOG) Study. Am J Clin Oncol 23(3):237–277
• (63). Kuznetsov G, TenDyke K, Towle MJ, Cheng H, Liu J, Marsh JP, Schiller SER, Spyvee MR, Yang H, Seletsky BM, Shaffer CJ, Marceau V, Yao Y, Suh EM, Campagna S, Fang FG, Kowalczyk JJ, Littlefield BA (2009) Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol Cancer Ther 8(10):2852–2860
• (64). LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O’Connor OA, Josephson N, Wang Y, Advani R (2018) Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 132(1):40–48
• (65). Lamers C (2022) Overcoming the shortcomings of peptide-based therapeutics. Future Drug Discov 4(2):FDD75
• (66). Law C-L, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF (2004) Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates. Clin Cancer Res 10(23):7842–7851
• (67). Lee Y, Phat C, Hong S-C (2017) Structural diversity of marine cyclic peptides and their molecular mechanisms for anticancer, antibacterial, antifungal, and other clinical applications. Peptides 95:94–105
• (68). Leoncini L, Lazzi S, Bellan C, Tosi P (2002) Cell kinetics and cell cycle regulation in lymphomas. J Clin Pathol 55(9):648
• (69). Li G, Tian Y, Zhu WG (2020a) The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol 8:576946
• (70). Li Z, Abadir E, Lee K, Clarke C, Bryant CE, Cooper W, Pietersz G, Favaloro J, Silveira PA, NJ Hart D, Ju X (2020b) Targeting CD83 in mantle cell lymphoma with anti?human CD83 antibody. Clin Trans Immunol 9(7):e1156.
• (71). Liang B, Richard DJ, Portonovo PS, Joullié MM (2001) Total Syntheses and Biological Investigations of Tamandarins A and B and Tamandarin A Analogs. J Am Chem Soc 123(19):4469–4474
• (72). Liu X, Tao X, Zou A, Yang S, Zhang L, Mu B (2010) Effect of themicrobial lipopeptide on tumor cell lines: apoptosis induced by disturbing the fatty acid composition of cell membrane. Protein Cell 1(6):584–594
• (73). Lunning MA, Ruan J, Nair S, Boruchov AM, Byrne R, Gerecitano JF, Hamlin PA, Inserra B, Leonard J, Lynch P, Matasar MJ, Moskowitz AJ, Moskowitz C, Myskowski PL, Nolan P, Palomba ML, Quefeld C, Straus DJ, Zelenetz AD, Horwitz SM (2014) A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results. J Clin Oncol 32(15_suppl):8582–8582
• (74). Maki A, Diwakaran H, Redman B, Al-Asfar S, Pettit GR, Mohammad RM, Al-Katib A (1995) The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs 6(3):392–397
• (75). Maki A, Mohammad R, Raza S, Saleh M, Govindaraju KD, Pettit GR, Al-Katib A (1996) Effect of dolastatin 10 on human non-Hodgkin’s lymphoma cell lines. Anticancer Drugs 7(3):344–350
• (76). Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, Morrione A, Giordano A, Cenciarelli C (2021) p53 signaling in cancer progression and therapy. Cancer Cell Int 21(1):703
• (77). Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G (2006) Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Annals Oncol 17(9):1371–1378
• (78). Marquez BL, Watts KS, Yokochi A, Roberts MA, Verdier-Pinard P, Jimenez JI, Hamel E, Scheuer PJ, Gerwick WH (2002) Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly. J Nat Prod 65(6):866–871
• (79). Matasar MJ, Haioun C, Sancho J-M, Viardot A, Hirata J, Perretti T, Musick L, McMillan AK (2021) POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood 138(Supplement 1):3568–3568
• (80). Mehta-Shah N, Lunning MA, Boruchov AM, Ruan J, Nair S, Lynch P, Byrne R, Moskowitz AJ, Matasar MJ, Gerecitano JF, Hamlin PA, Leonard J, Moskowitz CH, Myskowski PL, Querfeld C, Nolan P, Palomba ML, Straus DJ, Zelenetz AD, Horwitz SM (2015) A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma. J Clin Oncol 33(15_suppl):8521–8521
• (81). Miller ED, Kauffman CA, Jensen PR, Fenical W (2007) Piperazimycins: cytotoxic hexadepsipeptides from a marine-derived bacterium of the genus streptomyces. J Org Chem 72(2):323–330
• (82). Mohammad RM, Pettit GR, Almatchy VP, Wall N, Varterasian M, Ai-Katib A (1998) Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. Anti-Cancer Drugs 9(2):149–156
• (83). Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI (2019) Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 6(5):e254–e265
• (84). Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 385(9980):1853–1862
• (85). Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S (2018) Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood, J Am Soc Hematol 132(25):2639–2642
• (86). Muttenthaler M, King GF, Adams DJ, Alewood PF (2021) Trends in peptide drug discovery. Nat Rev Drug Discov 20(4):309–325
• (87). Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu W, Zheng Q (2022) Natural products as anticancer agents: current status and future perspectives. Molecules 27(23):8367
• (88). Odaka C, Sanders Miranda L, Crews P (2000) Jasplakinolide Induces Apoptosis in Various Transformed Cell Lines by a Caspase-3-Like Protease-Dependent Pathway. Clin Diagnostic Lab Immunol 7(6):947–952
• (89). Oh D-C, Jensen PR, Fenical W (2006) Zygosporamide, a cytotoxic cyclic depsipeptide from the marine-derived fungus Zygosporium masonii. Tetrahedron Lett 47(48):8625–8628
• (90). Ozcan M, Lee ST, Mensah F, Modi D, Fossa A, Seog Kim W, Paszkiewicz-Kozik E, Sawalha Y, Sevindik ÖG, Norasetthada L, Santoro A, Pathiraja K, Chakraborty S, Marinello P, Lavie D (2023) Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study. J Clin Oncol 41(16_suppl):7531–7531
• (91). Pangestuti R, Kim S-K (2017) Bioactive Peptide of Marine Origin for the Prevention and Treatment of Non-Communicable Diseases. Marine Drugs 15(3):67
• (92). Pazzaglia S (2019) Pioli C (2020) Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases. Cells 9(1):20
• (93). Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon S-J, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IBJ, Kipps TJ, Dick JE, Stover DR (2015) AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther 14(7):1650–1660
• (94). Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98(9):2865–2868
• (95). Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE (2009) Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. J Clin Oncol 27(32):5410–5417
• (96). Poetsch AR (2020) The genomics of oxidative DNA damage, repair, and resulting mutagenesis. Comput Struct Biotechnol J 18:207–219
• (97). Preta G (2020) New Insights Into Targeting Membrane Lipids for Cancer Therapy. Front Cell Dev Biol 8:571237
• (98). Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL (2017) Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390(10094):555–566
• (99). Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J (2022) The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol 12:985363
• (100). Ramadhani D, Maharani R, Gazzali AM, Muchtaridi M (2022) Cyclic Peptides for the Treatment of Cancers: A Review. Molecules 27(14):4428
• (101). Rashid MA, Gustafson KR, Cardellina JH, Boyd MR (1995) Patellamide F, a New Cytotoxic Cyclic Peptide from the Colonial Ascidian Lissoclinum patella. J Natural Products 58(4):594–597
• (102). Raucher D, Ryu JS (2015) Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol Med 21(9):560–570
• (103). Richardson NC, Kasamon YL, Chen H, de Claro RA, Ye J, Blumenthal GM, Farrell AT, Pazdur R (2019) FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma. Oncologist 24(5):e180–e187
• (104). Saide A, Damiano S, Ciarcia R, Lauritano C (2021) Promising activities of marine natural products against Hematopoietic Malignancies. Biomedicines 9(6):645
• (105). Sánchez-Beato M, Sánchez-Aguilera A, Piris MA (2003) Cell cycle deregulation in B-cell lymphomas. Blood 101(4):1220–1235
• (106). Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S (2002) Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 64(7):1079–1090
• (107). Sawas A, Savage KJ, Perez RP, Advani RH, Zaine JM, Lackey JM, Trave F, Anand B, Chu R, Reyno LM, O’Connor OA (2017) A Phase 1 study of the anti-CD37 antibody-drug conjugate AGS67E in advanced lymphoid malignancies. Interim Results Hematol Oncol 35(S2):49–49
• (108). Sedeta E, Ilerhunmwuwa N, Wasifuddin M, Uche I, Hakobyan N, Perry J, Aiwuyo H, Abowali H, Avezbakiyev B (2022) Epidemiology of Non-Hodgkin Lymphoma: Global Patterns of Incidence, Mortality, and Trends. Blood 140(Supplement 1):5234–5235
• (109). Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ (2019) Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 38(2):155–165
• (110). Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30(7):631–637
• (111). Shamloo B (2019) Usluer S (2019) p21 in Cancer Research. Cancers (Basel) 11(8):1178
• (112). Shanmugam G, Rakshit S, Sarkar K (2022) HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Trans Oncol 16:101312
• (113). Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y (2010) HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 24(10):1760–1768
• (114). Singh SB (2022) Discovery and development of dolastatin 10-derived antibody drug conjugate anticancer drugs. J Nat Prod 85(3):666–687
• (115). Smolewski P, Robak T (2017) The discovery and development of romidepsin for the treatment of T-cell lymphoma. Expert Opin Drug Discov 12(8):859–873
• (116). Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2020) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 71(3):209–249
• (117). Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, Warnke RA, Natkunam Y, Han SS, Yuen A, Plevritis SK, Advani RH (2013) Improvements in observed and relative survival in follicular grade 1–2 lymphoma during 4 decades: the Stanford University experience. Blood 122(6):981–987
• (118). Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA (2014) Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 32(6):1246–1257
• (119). Tilly H, Flowers C, Friedberg JW, Herbaux C, Morschhauser F, Sehn LH, Sharman JP, Trneny M, Lee C, Salles GA (2019) POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. J Clin Oncol 37(15):TPS7571
• (120). Villadsen JS, Kitir B, Wich K, Friis T, Madsen AS, Olsen CA (2014) An azumamide C analogue without the zinc-binding functionality. MedChemComm 5(12):1849–1855
• (121). Vincent R, Dolores C, Christophe F, Emanuele Z, Reyes A, Javier B, Christian G, Gilles S, Alessandro MG, Henry G, Carmen K, Claudia C, Sergio S, Sonia E, de Bernardo M, Martin C-Y, Franco C (2013) Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma. Haematologica 98(3):357–363
• (122). Vinogradov AA, Suga H (2020) Introduction to Thiopeptides: Biological Activity, Biosynthesis, and Strategies for Functional Reprogramming. Cell Chem Biol 27(8):1032–1051
• (123). Wagner MM, Paul DC, Shih C, Jordan MA, Wilson L, Williams DC (1999) In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother Pharmacol 43(2):115–125
• (124). Wang X, Gong X, Li P, Lai D, Zhou L (2018) Structural diversity and biological activities of cyclic depsipeptides from fungi. Molecules 23(1):169
• (125). Wang P, Wang Z, Liu J (2020) Role of HDACs in normal and malignant hematopoiesis. Mol Cancer 19(1):5
• (126). Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C (2022a) Therapeutic peptides: current applications and future directions. Signal Transduction Targeted Ther 7(1):48
• (127). Wang M, Mei M, Barr PM, Barrientos J, de Vos S, Furman R, Patel K, Thompson PA, Choi M, Kallam A, Zhu Y, Chakraborty S, Marinello P, Spurgeon SE (2022b) P1231: Zilovertamab vedotin (MK-2140) for the treatment of Non-Hodgkin Lymphoma: The phase 1 dose escalation and cohort expansion WAVELINE-001 study of an anti-ROR1 antibody-drug conjugate. HemaSphere 6:1116–1117
• (128). Zhang J-N, Xia Y-X, Zhang H-J (2021a) Natural Cyclopeptides as Anticancer Agents in the Last 20 Years. Int J Mol Sci 22(8):3973
• (129). Zhang QT, Liu ZD, Wang Z, Wang T, Wang N, Wang N, Zhang B, Zhao YF (2021b) Recent advances in small peptides of marine origin in cancer therapy. Mar Drugs 19(2):2515
• (130). Zhou L, Yang J, Zhang K, Wang T, Jiang S, Zhang X (2024) Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b). J Med Chem 67(2):816–837
• (131). Zobeida C-M, Hélène CV, Ruoli B, David JN, Stephen BH, Gerrit L, Jeffrey TM, Michael DW, George RP, William F, Ernest H (2003) Diazonamide A and a Synthetic Structural Analog: Disruptive Effects on Mitosis and Cellular Microtubules and Analysis of Their Interactions with Tubulin. Mol Pharmacol 63(6):1273
• (132). Zullo K, Guo Y, Cooke L, Serrano XJ, Mangone M, Scotto L, Amengual JE, Mahadevan D, O’Connor OA (2014) The Investigational aurora a kinase inhibitor alisertib exhibits broad activity in preclinical models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin. Blood 124(21):4493–4493

---

More Article by Dr. Salman Ahmed